Apeiron, based in Vienna, Austria, is focused on the development of novel cancer Immunotherapies.

Biotechnology

APEIRON Biologics

APEIRON Biologics' headquarters in Wien, Austria

Caroline Baeumler-Klestil

Gerald Wirnsberger

Alexander Dohnal

Michael Ruppert

Marko Poglitsch

Gerhard Wallner

 Mag Rainer C. Burian

Josef Penninger

Erwin Rasinger

Helmut Schuehsler

Daniel D. Von Hoff

Ruth Ladenstein

Hans Loibner

Anthony El-Khoueiry

Paul Sondel

Angela Alistar

Marc Albertini

Holger Lode

Ulrich Granzer

Manfred Reichl

Pierre L. Triozzi

The Advisory Team at APEIRON Biologics provides strategic guidance and expert recommendations to steer the company in advancing novel cancer immunotherapies. Comprising Supervisory Board Members, Advisors, and a Strategic Advisor, the team ensures that the company’s development programs align with industry standards and long-term corporate goals.

Advisory Team

The Project Management team at APEIRON Biologics coordinates the development of innovative cancer immunotherapies. They oversee project timelines, resource allocation, and cross-functional collaboration, ensuring the seamless progression from preclinical to clinical stages. This team plays a pivotal role in driving projects towards successful regulatory approval and market release.

Project Management

The Leadership Team at APEIRON Biologics is responsible for guiding the strategic direction of the company in the development of innovative cancer immunotherapies. This team, comprising key executives such as the Chief Medical Officer and Chief Development Officer, collaborates to align research initiatives, regulatory strategies, and clinical trial operations, ensuring that the company meets its mission of advancing effective treatment options for cancer patients.

Leadership Team

APEIRON Biologics

Org chart

Board & advisors

Teams

Advisory Team

Project Management

Leadership Team

Offices

APEIRON Biologics

Org chart

Board & advisors

Teams

Advisory Team

Project Management

Leadership Team

Offices

Related companies